RS BioTherapeutics
Cumberland, US · Founded 2021 · Delaware corporation
RS BioTherapeutics is a biopharmaceutical company developing therapeutics for respiratory diseases characterized by pulmonary inflammation. Its lead compound, RSBT-001, is a cannabinoid-based, first-in-class alternative to corticosteroids in development for conditions including COPD, idiopathic pulmonary fibrosis, and pulmonary arterial hypertension.
Founders & leadership
MG
Michael GuzmaninChief Of Staff
HD
H. Dean HartinChief Executive Officer2022–2025
CR
Curtis RhineinChief Financial Officer2023–2025
JM
Justin MolignoniinBoard Chair/Chief Strategy Officer
DF
Dustin FreasNamed on SEC filing
Board
DF
David FreasBoard director
Reported raises · per SEC filings
Form D private placements$1.9M disclosed across 4 rounds · 2022–2024
▶$20KraisedOct 2024 · 1 investors · Other Health CareRule 506(b)
▶$20KraisedOct 2024 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Michael GuzmanExecutive Officer
- H. Dean HartExecutive Officer
- Curtis RhineExecutive Officer
- Justin MolignoniExecutive Officer, Director
- David FreasDirector
- Offering amount
- $2M
- Amount sold
- $20K
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$1.1MraisedOct 2023 · 5 investors · PharmaceuticalsRule 506(b)
▶$1.1MraisedOct 2023 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Curtis RhineExecutive Officer
- Michael GuzmanExecutive Officer
- H. Dean HartExecutive Officer
- David FreasDirector
- Justin MolignoniExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $1.1M
- Minimum investment
- $50K
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$100KraisedMar 2023 · 1 investors · PharmaceuticalsRule 506(b)
▶$100KraisedMar 2023 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- H. Dean HartExecutive Officer
- Curtis RhineExecutive Officer
- Dustin FreasDirector
- Justin MolignoniExecutive Officer, Director
- Michael GuzmanExecutive Officer
- Offering amount
- $10M
- Amount sold
- $100K
- Minimum investment
- $50K
- Proceeds to insiders
- $1.6M
- First sale
- Nov 2022
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$685KraisedJun 2022 · 6 investors · PharmaceuticalsRule 506(b)
▶$685KraisedJun 2022 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Justin MolignoniExecutive Officer, Director
- Michael GuzmanExecutive Officer
- H. Dean HartExecutive Officer
- Dustin FreasExecutive Officer, Director
- Offering amount
- $4M
- Amount sold
- $685K
- Minimum investment
- $50K
- Proceeds to insiders
- $886.7K
- First sale
- Jun 2022
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapSarepta Therapeutics3 shared keywordsSarepta develops precision genetic medicines for people with rare diseases, with a focus on rare neuromuscular conditions. The company also runs an investigator-initiated studies program that funds independent clinical and non-clinical research in its therapeutic areas.
Risetherapeutics3 shared keywordsRise Therapeutics develops oral immunotherapies, called Oral Immune BioModulators, using a synthetic biology-based drug design approach to treat autoimmune diseases and cancer. The company combines immunology research with in-house clinical GMP manufacturing and regulatory expertise to advance its pipeline through clinical validation.
Companies competing with RS BioTherapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does RS BioTherapeutics do?
- RS BioTherapeutics is a biopharmaceutical company developing therapeutics for respiratory diseases characterized by pulmonary inflammation. Its lead compound, RSBT-001, is a cannabinoid-based, first-in-class alternative to corticosteroids in development for conditions including COPD, idiopathic pulmonary fibrosis, and pulmonary arterial hypertension.
- How much funding has RS BioTherapeutics raised?
- RS BioTherapeutics has disclosed $1.9M raised across 4 rounds.
- Where is RS BioTherapeutics headquartered?
- RS BioTherapeutics is headquartered in Cumberland, US.